StemCell Therapy

Hyderabad, June 6 (UNI) Technology Business Incubator Birla Institute of Technology and Science (BITS) Pilani, Hyderabad has collaborated with American Association for Precision Medicine (AAPM) and World Investors and Entrepreneurs Summit (WISE) to conduct the 'Precision Medicine 2022' event at its campus here on Tuesday with the theme of Precision Medicine, Artificial Intelligence (AI) & the Future of Personalized Health care.This event brings together top experts and thought leaders in precision medicine, life science, biotech, MedTech, and pharma. It is designed to bring the community together and serve as a leading forum for new medical breakthroughs and cutting-edge basic, translational, and clinical research, BITS Pilani said in a release here on Monday.

To fulfill this vision, we will be showcasing thought leaders involved in innovative research, developing new capabilities, and developing technological interventions to speed up the delivery of personal health. The biggest Precision Medicine event will also showcase new solutions to clinical and omics data collection, transfer, storage, analysis, security, and design/implement new Big Data Solutions and AI.UNI KNR CS1206

Here is the original post:
BITS Pilani Hyderabad to conduct 'Precision Medicine 2022' event tomorrow - United News of India

ReportLinker

Abstract: What`s New for 2022? - Global competitiveness and key competitor percentage market shares. - Market presence across multiple geographies - Strong/Active/Niche/Trivial.

New York, June 07, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Laboratory Information Systems (LIS) Industry" - https://www.reportlinker.com/p05957217/?utm_source=GNW - Online interactive peer-to-peer collaborative bespoke updates - Access to our digital archives and MarketGlass Research Platform - Complimentary updates for one year - Global Laboratory Information Systems (LIS) Market to Reach US$2.4 Billion by the Year 2026

- LIS is advanced software that stores and manages data in laboratories, and is used for sending test orders, recording laboratory test results, sorting data in databases. These platforms are widely used by clinics, hospitals and diagnostic laboratories to maintain data related to tests and medical history of patients, track data quality and send laboratory test orders. The demand for LIS is driven by their ability to enhance productivity, allow precise and accurate diagnosis, reduce diagnostic errors and improve patient satisfaction. The global market is poised to register significant growth in the future due to various factors such as rising incidence of chronic diseases, the huge volume of test data obtained from clinical testing, the need for enhanced lab automation and efficiency. The global market for these systems is also propelled by increasing adoption of digital solutions to store, retrieve and maintain data in real-time. These systems are offered by sophisticated analytic tools to deal with healthcare issues and improve overall productivity. The market is gaining from the need to reduce diagnostic errors, use of LIS to boost laboratory workflow efficiency, and incorporation of these systems with EHR systems. However, factors such as high maintenance cost, shortage of skilled professionals, and need for specialized laboratories remain key challenges for the market. On the other hand, huge investments by governments in LIS, increasing need for customized systems with data security functions and availability of advanced platforms are expected to present new growth avenues for the market. Rising adoption of laboratory automation and advances in R&D, particularly in biotechnology and pharmaceutical industries, are slated to push the market growth.

- Amid the COVID-19 crisis, the global market for Laboratory Information Systems (LIS) estimated at US$1.7 Billion in the year 2022, is projected to reach a revised size of US$2.4 Billion by 2026, growing at a CAGR of 9.2% over the analysis period. Standalone, one of the segments analyzed in the report, is projected to grow at a 6.6% CAGR to reach US$1.3 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Integrated segment is readjusted to a revised 12.2% CAGR for the next 7-year period. This segment currently accounts for a 41.9% share of the global Laboratory Information Systems (LIS) market. Based on product, standalone LIS segment is poised to hold a major share of the market during the analysis period, owing to key factors such as user-friendly nature, enhanced data security, affordability, and ability to work offline. As standalone LIS are not part of a software package, their ability to work offline augments its implementation. Technological innovations is also expected to further boost demand for standalone LIS. Integrated LIS is projected to witness faster growth during the analysis period. Against a backdrop of rising adoption of EMR, healthcare institutions are striving to achieve interoperability and standardization. This in turn spurred the shift from best-of-breed or standalone LIS to deployment of enterprise-wide integrated LIS. Integrated LIS lower dependencies on interfaces, vendor contracts, and total cost of ownership. The U.S. Market is Estimated at $825.5 Million in 2022, While China is Forecast to Reach $148.5 Million by 2026

- The Laboratory Information Systems (LIS) market in the U.S. is estimated at US$825.5 Million in the year 2022. The country currently accounts for a 52.9% share in the global market. China, the world`s second largest economy, is forecast to reach an estimated market size of US$148.5 Million in the year 2026 trailing a CAGR of 12.2% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7% and 7.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.1% CAGR while Rest of European market (as defined in the study) will reach US$166.8 Million by the close of the analysis period. The US is at the forefront of adoption of LIS systems and dominates the global market, owing to favorable reimbursement policies in the country, for pathology procedures. The region is exhibiting strong gains on account of technological advancements and expansion of the healthcare sector, encompassing clinical research laboratories and diagnostic centers. Europe is another lucrative market for LIS. Developed countries like Germany for instance, are increasingly embracing automation in healthcare for reducing need for workforce. Healthcare providers in such markets are eagerly focusing on deploying automation like LIS for providing quality care to patients. The LIS market in Asia-Pacific, mainly China, is projected to post the fastest growth rate in the coming years due to extensive penetration of these systems in the region on account of surge in personalized medicine demand in the country and also rapid propagation of cloud LIS. Select Competitors (Total 254 Featured) Cerner Corporation Cirdan Comp Pro Med, Inc. CompuGroup Medical AG Margy Tech Pvt Ltd. McKesson Corporation Meditech Orchard Software Corporation Soft Computer Consultants Inc. Sunquest Information Systems, Inc. XIFIN Inc.

Read the full report: https://www.reportlinker.com/p05957217/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW Impact of Covid-19 and a Looming Global Recession The Never-Ending ?Race? Between the Virus & Vaccines Continues. Amidst this Chaotic Battle, Where is the World Economy Heading Now & Beyond? Omicron Variant Brings Back Memories & Fears of the Worst Part of the 2020 Pandemic EXHIBIT 1: Time is of Essence! What We Know So Far - ?Vaccine Efficiency Against New Strains? With New Strains Emerging at an Alarming Rate, Focus Shifts to Booster Doses & Vaccine Tweaking. But How Practical Is It to Implement Them? EXHIBIT 2: With Vaccinated Population Showing Signs of Declining Clinical Protection, Booster Doses Are Emerging Into a Necessity to Restore Vaccine Effectiveness: Number of Booster Doses Administered Per 100 People by Country as of December 2021 With IMF Making an Upward Revision of Global GDP for 2022, Companies Are Bullish About a Continuing Economic Comeback Despite a Prolonging Pandemic EXHIBIT 3: A Strong Yet Uncertain Recovery Shaped by New Variants Comes Into Play: World Economic Growth Projections: (Real GDP, Annual % Change) for 2020 through 2022 Overwhelming COVID-19 Testing Volumes Elevate Demand for Laboratory Information Systems EXHIBIT 4: Laboratory Information Systems (LIS) - Global Key Competitors Percentage Market Share in 2022 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for 254 Players Worldwide in 2022 (E) A Prelude to Laboratory Information Systems (LIS) Functions of an Effective LIS Global Laboratory Information Systems Market to Witness Rapid Growth Standalone LIS Holds Major Share Services Segment Dominates the LIS Market, Software to Witness Higher Growth during the Forecast Period On-Premise LIS Holds Major Share Due to Customization Benefits Cloud-based LIS Model to Grow in Prominence due to Many Benefits Offered over Traditional, On-Premise Models US Holds Clear Edge over Other Regions, Asia-Pacific to Exhibit Fastest Growth RECENT MARKET ACTIVITY

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS Introduction of Advanced Technologies Fuel Demand for Laboratory Information Systems Digitization of Healthcare Drives Integration of LIS Accelerating Pace of Digital Pathology Increase Adoption Increasing Concerns Pertaining to Data Integrity Fuel Demand for Laboratory Information Systems Introduction of Stringent Data Protection Guidelines Propel Demand for Laboratory Information System Software Use of Easy to Integrate Laboratory Information Systems Gain Momentum Artificial Intelligence Gains Prominence EXHIBIT 5: AI Spending in Healthcare & Life sciences in US$ Million for Years 2020 & 2025 Burgeoning Population and Rising Incidence of Chronic Diseases: A Key Market Driver for LIS EXHIBIT 6: Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others EXHIBIT 7: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040 EXHIBIT 8: Breakdown of Total Number of Cancer Cases by Cancer Site: 2020 EXHIBIT 9: Rising Diabetes Prevalence Presents Opportunity for iPSCs Market: Number of Adults (20-79) with Diabetes (in Millions) by Region for 2017 and 2045 Aging Demographics Add to the Global Burden of Chronic Diseases, Presenting Opportunities for Laboratory Information System/LIS market EXHIBIT 10: Expanding Elderly Population Worldwide: Breakdown of Number of People Aged 65+ Years in Million by Geographic Region for the Years 2019 and 2030 Growing Adoption of Laboratory Automation Drives the Need for LIS Rise of Laboratory 4.0 to Spur the Adoption of LIS EXHIBIT 11: World Laboratory Automation Market in US$ Billion for Years 2018, 2020, 2022, 2024 & 2026 Laboratory Information Systems Gain Traction amidst Growing Need to Enhance Workflow Efficiencies and Reduce Costs Rise in Molecular Testing Volumes to Elevate Demand EXHIBIT 12: Global Genetic Testing Market in US$ Million: 2015, 2020, & 2025 Improving Healthcare Expenditure to Turbo Charge Future Growth of the Market EXHIBIT 13: World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023 EXHIBIT 14: Elderly Healthcare Expenditure as a % of GDP Need to Improve Diagnostics Accuracy Increasing Popularity of Enterprise LIS Rise in Consolidation of Healthcare Providers Creates Need for Robust and Comprehensive LIS Growing Emphasis on Personalized Medicine to Support Growth EXHIBIT 15: Global Personalized Medicine Market: Revenues in US$ Million for the Years 2019, 2021, 2023 and 2025 Rise in Investment in R&D Activity to Spur Growth Shortage of Trained Professionals Hinders Adoption Rate

4. GLOBAL MARKET PERSPECTIVE Table 1: World Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Laboratory Information Systems (LIS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Laboratory Information Systems (LIS) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2021 & 2027

Table 4: World Recent Past, Current & Future Analysis for Standalone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for Standalone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Standalone by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027

Table 7: World Recent Past, Current & Future Analysis for Integrated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 8: World Historic Review for Integrated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 9: World 15-Year Perspective for Integrated by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027

Table 10: World Recent Past, Current & Future Analysis for On-Premise by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 11: World Historic Review for On-Premise by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 12: World 15-Year Perspective for On-Premise by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027

Table 13: World Recent Past, Current & Future Analysis for Cloud by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 14: World Historic Review for Cloud by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 15: World 15-Year Perspective for Cloud by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027

Table 16: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 17: World Historic Review for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027

Table 19: World Recent Past, Current & Future Analysis for Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 20: World Historic Review for Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Software by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027

Table 22: World Recent Past, Current & Future Analysis for Hospital Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 23: World Historic Review for Hospital Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 24: World 15-Year Perspective for Hospital Laboratories by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027

Table 25: World Recent Past, Current & Future Analysis for Independent Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 26: World Historic Review for Independent Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 27: World 15-Year Perspective for Independent Laboratories by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027

Table 28: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 29: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 30: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027

III. MARKET ANALYSIS

UNITED STATES Laboratory Information Systems (LIS) Market Presence - Strong/ Active/Niche/Trivial - Key Competitors in the United States for 2022 (E) Market Analytics Table 31: USA Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Product - Standalone and Integrated - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 32: USA Historic Review for Laboratory Information Systems (LIS) by Product - Standalone and Integrated Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 33: USA 15-Year Perspective for Laboratory Information Systems (LIS) by Product - Percentage Breakdown of Value Revenues for Standalone and Integrated for the Years 2012, 2021 & 2027

Table 34: USA Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Deployment - On-Premise and Cloud - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 35: USA Historic Review for Laboratory Information Systems (LIS) by Deployment - On-Premise and Cloud Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 36: USA 15-Year Perspective for Laboratory Information Systems (LIS) by Deployment - Percentage Breakdown of Value Revenues for On-Premise and Cloud for the Years 2012, 2021 & 2027

Table 37: USA Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Component - Services and Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 38: USA Historic Review for Laboratory Information Systems (LIS) by Component - Services and Software Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 39: USA 15-Year Perspective for Laboratory Information Systems (LIS) by Component - Percentage Breakdown of Value Revenues for Services and Software for the Years 2012, 2021 & 2027

Table 40: USA Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by End-Use - Hospital Laboratories, Independent Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 41: USA Historic Review for Laboratory Information Systems (LIS) by End-Use - Hospital Laboratories, Independent Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 42: USA 15-Year Perspective for Laboratory Information Systems (LIS) by End-Use - Percentage Breakdown of Value Revenues for Hospital Laboratories, Independent Laboratories and Other End-Uses for the Years 2012, 2021 & 2027

CANADA Table 43: Canada Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Product - Standalone and Integrated - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 44: Canada Historic Review for Laboratory Information Systems (LIS) by Product - Standalone and Integrated Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 45: Canada 15-Year Perspective for Laboratory Information Systems (LIS) by Product - Percentage Breakdown of Value Revenues for Standalone and Integrated for the Years 2012, 2021 & 2027

Table 46: Canada Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Deployment - On-Premise and Cloud - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 47: Canada Historic Review for Laboratory Information Systems (LIS) by Deployment - On-Premise and Cloud Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 48: Canada 15-Year Perspective for Laboratory Information Systems (LIS) by Deployment - Percentage Breakdown of Value Revenues for On-Premise and Cloud for the Years 2012, 2021 & 2027

Table 49: Canada Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Component - Services and Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 50: Canada Historic Review for Laboratory Information Systems (LIS) by Component - Services and Software Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 51: Canada 15-Year Perspective for Laboratory Information Systems (LIS) by Component - Percentage Breakdown of Value Revenues for Services and Software for the Years 2012, 2021 & 2027

Table 52: Canada Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by End-Use - Hospital Laboratories, Independent Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 53: Canada Historic Review for Laboratory Information Systems (LIS) by End-Use - Hospital Laboratories, Independent Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 54: Canada 15-Year Perspective for Laboratory Information Systems (LIS) by End-Use - Percentage Breakdown of Value Revenues for Hospital Laboratories, Independent Laboratories and Other End-Uses for the Years 2012, 2021 & 2027

JAPAN Table 55: Japan Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Product - Standalone and Integrated - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 56: Japan Historic Review for Laboratory Information Systems (LIS) by Product - Standalone and Integrated Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 57: Japan 15-Year Perspective for Laboratory Information Systems (LIS) by Product - Percentage Breakdown of Value Revenues for Standalone and Integrated for the Years 2012, 2021 & 2027

Table 58: Japan Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Deployment - On-Premise and Cloud - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 59: Japan Historic Review for Laboratory Information Systems (LIS) by Deployment - On-Premise and Cloud Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 60: Japan 15-Year Perspective for Laboratory Information Systems (LIS) by Deployment - Percentage Breakdown of Value Revenues for On-Premise and Cloud for the Years 2012, 2021 & 2027

Table 61: Japan Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Component - Services and Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 62: Japan Historic Review for Laboratory Information Systems (LIS) by Component - Services and Software Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 63: Japan 15-Year Perspective for Laboratory Information Systems (LIS) by Component - Percentage Breakdown of Value Revenues for Services and Software for the Years 2012, 2021 & 2027

Table 64: Japan Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by End-Use - Hospital Laboratories, Independent Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 65: Japan Historic Review for Laboratory Information Systems (LIS) by End-Use - Hospital Laboratories, Independent Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 66: Japan 15-Year Perspective for Laboratory Information Systems (LIS) by End-Use - Percentage Breakdown of Value Revenues for Hospital Laboratories, Independent Laboratories and Other End-Uses for the Years 2012, 2021 & 2027

CHINA Table 67: China Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Product - Standalone and Integrated - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 68: China Historic Review for Laboratory Information Systems (LIS) by Product - Standalone and Integrated Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 69: China 15-Year Perspective for Laboratory Information Systems (LIS) by Product - Percentage Breakdown of Value Revenues for Standalone and Integrated for the Years 2012, 2021 & 2027

Table 70: China Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Deployment - On-Premise and Cloud - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 71: China Historic Review for Laboratory Information Systems (LIS) by Deployment - On-Premise and Cloud Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 72: China 15-Year Perspective for Laboratory Information Systems (LIS) by Deployment - Percentage Breakdown of Value Revenues for On-Premise and Cloud for the Years 2012, 2021 & 2027

Table 73: China Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Component - Services and Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 74: China Historic Review for Laboratory Information Systems (LIS) by Component - Services and Software Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 75: China 15-Year Perspective for Laboratory Information Systems (LIS) by Component - Percentage Breakdown of Value Revenues for Services and Software for the Years 2012, 2021 & 2027

Table 76: China Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by End-Use - Hospital Laboratories, Independent Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 77: China Historic Review for Laboratory Information Systems (LIS) by End-Use - Hospital Laboratories, Independent Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 78: China 15-Year Perspective for Laboratory Information Systems (LIS) by End-Use - Percentage Breakdown of Value Revenues for Hospital Laboratories, Independent Laboratories and Other End-Uses for the Years 2012, 2021 & 2027

EUROPE Laboratory Information Systems (LIS) Market Presence - Strong/ Active/Niche/Trivial - Key Competitors in Europe for 2022 (E) Market Analytics Table 79: Europe Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 80: Europe Historic Review for Laboratory Information Systems (LIS) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 81: Europe 15-Year Perspective for Laboratory Information Systems (LIS) by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2021 & 2027

Table 82: Europe Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Product - Standalone and Integrated - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 83: Europe Historic Review for Laboratory Information Systems (LIS) by Product - Standalone and Integrated Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 84: Europe 15-Year Perspective for Laboratory Information Systems (LIS) by Product - Percentage Breakdown of Value Revenues for Standalone and Integrated for the Years 2012, 2021 & 2027

Table 85: Europe Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Deployment - On-Premise and Cloud - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 86: Europe Historic Review for Laboratory Information Systems (LIS) by Deployment - On-Premise and Cloud Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 87: Europe 15-Year Perspective for Laboratory Information Systems (LIS) by Deployment - Percentage Breakdown of Value Revenues for On-Premise and Cloud for the Years 2012, 2021 & 2027

The rest is here:
Global Laboratory Information Systems (LIS) Market to Reach US$2.4 Billion by the Year 2026 - Yahoo Finance

Medical Nutrition Market: Complementarity of Pharmacology & Nutrition to Augur Well for Growth

As old health rules are overturned, a physiological approach that starts from health in place of disease is gaining high emphasis. Hippocrates quote, Let food be thy medicine and medicine be thy food has been put into practice, as individuals are considering medical nutrition and food for enhancing health and treating disease, despite the developments procured in the field of medical science.

Get Brochure of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1704

The idea of disease prevention to avoid or simplify complicated therapeutics is supported by the convergence of the pharmaceutical and food industry. In the past years, literatures have stated that the gap between nutrition science and pharmacology has been narrowing, a progress stirred by both disciplines. The only substances considered pharmacologically active in the past were drugs. Progressing on these terms, medical nutrition, the new treatment pattern entails on the fact that nutrients can have an intense effect on metabolic, immunological and other pathophysiological processes of unhealthy patients.

TMR, in its new research study, reveals compelling insights into the medical nutrition space, to assist readers with data-driven decision making. According to the TMR study, revenues from the medical nutrition market closed in on a valuation of over US$ 13,000 Mn in 2018. This growth is attributed to the growing awareness of chronic diseases among consumers coupled with the various initiatives and programs commenced for the effective prevention and control of these diseases. This has led to the growing inclination towards medical nutrition supplements.

Developments in biotechnology has further resulted in the revolution of the medical nutrition market as key manufacturers are concentrating on research and development of improved and personalized medical nutrition offerings. Moreover, the development of disease-specific specialized solution for the medical nutrition markets is also observed, particularly in the developed economies.

Enquiry Before Buying: https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=1704

From industry giants to first-movers, enterprises have long been in mercy of revolutionizing industry trends. Key trends shaping the medical nutrition landscape are discussed below.

Get COVID-19 Analysis https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1704

The digestive wellness trend embodies the increasing awareness around new ingredients, nutritional products which are based on the public health recommendations and science. This is led to the reduction of sugar content of foods. According to reports, a large part of the consumer base prefers the consumption of health-improving ingredients through food, as consumers care about nutrition with which they gain a control over their health and lifestyle. Foods that help reduce the gastrointestinal symptoms including the free-from foods, added-benefits ingredients,fermented foods, prebiotics, andprobioticsare gaining focus with this trend.

Driven by key developments in technology along with the continual progress attained by the field of science, the personalized medical nutrition has become much more than just a concept. Medical nutrition solutions providers are incorporating multidisciplinary approach to set up centers that focus on development of nutritional products that cater to specific needs. The future of personalized medical nutrition is cited to be fully individualized backed with constant monitoring of personalized information including gut bacteria, biomarkers or genes.

Explore More Related Reports:

Vegetable Oils Market https://www.transparencymarketresearch.com/vegetable-oil-market.htmlHerbal Extracts in Nutraceuticals Market https://www.transparencymarketresearch.com/herbal-extracts-in-nutraceuticals-market.htmlMoringa Supplements Market https://www.transparencymarketresearch.com/moringa-supplements-market.htmlChelated Minerals Market https://www.transparencymarketresearch.com/chelated-minerals-market.htmlLivestock Cake Market https://www.transparencymarketresearch.com/livestock-cake-market.html

About Us:

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision

Contact:

Rohit BhiseyTransparency Market Research Inc.CORPORATE HEADQUARTER DOWNTOWN,1000 N. West Street,Suite 1200, Wilmington, Delaware 19801 USATel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Email:[emailprotected]Website:https://www.transparencymarketresearch.com/

View post:
Medical Nutrition Market Promising Growth Opportunities and Forecast 2027 - Digital Journal

Published on June 7, 2022

Bengaluru: A new whitepaper, commissioned by Lenovo & Intel, led by IDC, highlights key challenges and drivers transforming the healthcare landscape across Asia Pacific. Titled Leveraging High-Performance Compute Infrastructure to Address the Genomic Data Challenge in Life Sciences, the paper underlines humanitys greatest challenges where genomics research-led intervention could impact significantly. A key highlight from the paper states that while the pandemic-led acceleration in innovation has given a boost to the Indian healthcare sector, genomics high-performance computing (HPC) infrastructure that is key to drug/vaccine discovery & precision medicine, is still at a startup stage for nearly 57% of surveyed organizations in India. This trend is also seen across a few other APAC regions surveyed: Japan and Korea lead in having advanced (3+ years) infrastructure.

The survey was conducted across 150 pharmaceutical and biotech companies across five key markets in Asia India, Singapore, Thailand, Japan, and Korea.

Genomics and Humanitys Greatest Challenges:

When it comes to solving biggest challenges facing societies and mankind, 40% of decision makers in India are certain that genomics is fundamental to developing a precision medicine strategy to treat chronic illness, rare diseases, and lifestyle disorders. Unsurprisingly, 33% of the organizations surveyed across Asia Pacific mirror this drift, followed by 21% who believe genomics can improve development of drugs and vaccines which is also a priority for 20% organizations in India.

Distinctive aspects discovered in the white paper point to the expansive potential of genomics. One being able to impact hunger and malnutrition, which has been ranked as the second greatest challenge across 40% of decision makers. According to 30% of surveyed leaders in India, genomics could also be a game-changer in helping to improve the environment as climate change continues to be a serious cause of concern.

Commenting on this, Sinisa Nikolic, Director and Segment Leader, HPC & AI, AP, Lenovo ISG, said, The volume and type of genomics data generated is unimaginable and to make accurate decisions based on this data requires huge computing power. This gets even more difficult with complex and unscalable solutions that were found to be cautious factors for 50% of organizations in India looking for genomics solutions.

Increasing Genomic Workloads and Storage Capabilities:

The trend towards developing niche, high-value personalized health solutions is expected to boom as 83% of organizations in India anticipate their annual genomics workloads to grow more than 10% over the next two years. Similarly, for 80%, the annual spend on data storage and compute is likely to increase more than 10% in the two-years period.

Sumir Bhatia, President AP, Lenovo ISG, said, One size doesnt fit all, whether at frontend healthcare delivery or backend IT infrastructure. To catchup with the ever-growing data, the required infrastructure setup can immensely add to the capital and operational expenditure. We expect this to be a critical challenge for organizations in India working to enhance their HPC infrastructure. This is where pay-as-you-go models like Lenovo TruScale become crucial so businesses of all sizes can scale up & down as required, and easily manage their operational expenditure to address humanitys greatest challenges.

The growing storage requirement predictions could add to the existing cost burdens for 33% of organizations who are currently spending more than $1M annually on data compute, storage, and maintenance & services. Even with the challenges around scalability, flexibility, and costs, nearly half (46.7%) of the respondents are not looking to acquire new solutions to transform their HPC landscape. Surprisingly, similar feedback was given by 50 percent of the leaders in Asia.

Recognizing IT Challenges and Accelerating Genomics Transformation with HPC:

With a growing focus on making precision medicine a reality, nearly 47% of decision-makers in Indias genomics industry feel that, with the high velocity at which genome data is generated, the lack of computing power to analyze it becomes the biggest infrastructural challenge for genome sequencing. Delving further into the challenges, 40% of the respondents ranked multi-dimensionality of data as the second-big IT challenge.

Close to 97% of respondents in India are using high-performance workstations and nearly 23% also use laptops for data visualization. Interestingly, 46% are using 3D augmented reality/virtual reality (AR/VR) solutions, indicating a growing shift toward immersive visualization techniques, complemented by deep learning to enable molecular modeling and simulations.

A major challenge for researchers is the time taken to process a single genome. Fortunately, solutions like Lenovo Genomics Optimization and Scalability Tool (GOAST) reduce the time to process a single human genome from 150 hours to less than 48 minutes. This enables researchers to quickly map a cohort of people instead of spending time analyzing a single genome. HPC supports high-throughput volumes to accelerate the speed of analysis, whereas AI helps make sense of the difference between genomes. This is why we are seeing GOAST being preferred by nearly 37% of organizations in India and expecting it to grow tremendously over the next few years. Sinisa Nikolic added.

In the entire context of genomics data, cyberthreats are a key challenge for only 3% of the organizations in India, while more than 80% feel strongly of their cybersecurity strategy indicating it as lowest amongst the hurdles.

Go here to read the rest:
57% of Organizations in India are at the Startup Stage of Genomics High-Performance Computing Infrastructure - APN News

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

myCare-024-04 Study Finds Cellworks Personalized Biosimulation Provides Superior OS and PFS Predictions for GBM Patients Beyond Standard Clinical Factors

CHICAGO--(BUSINESS WIRE)--

Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced results from the myCare-024-04 study, which demonstrate that the Cellworks Singula Therapy Response Index (TRI) was strongly predictive of Overall Survival (OS) and Progression-Free Survival (PFS) for newly diagnosed Glioblastoma Multiforme (GBM) patients. In this study, Singula TRI provided patient-specific estimates of OS and PFS for 18 NCCN guideline GBM therapies and provided predictive value beyond physician-prescribed therapy, patient age, patient sex, and MGMT methylation status.

The results from the myCare-024-04 clinical study were featured in a poster presentation with comments from Dr. Manmeet Ahluwalia, M.D., M.B.A., Chief of Medical Oncology, Chief Scientific Officer and Deputy Director at Miami Cancer Institute, part of Baptist Health South Florida, at the 2022 ASCO Annual Meeting June 3-7th during the Central Nervous Systems Tumors Session and available online as Abstract 2053.

The molecular heterogeneity of GBM is a key driver for the inconsistent therapy response rates that we see in brain cancer patients and makes the disease difficult to treat, said Patrick Wen, MD, Director, Center for Neuro-oncology, Dana-Farber Cancer Institute; Professor, Neurology, Harvard Medical School; and Co-Principal Investigator for the myCare-024-04 clinical study. But by using a patients NGS data and Cellworks Singula to biosimulate their individual therapy responses, we can potentially improve the ability to select the most effective therapy for each GBM patient and positively effect clinical outcomes for brain cancer patients.

The significant differences in treatment response among GBM patients necessitates moving beyond population-based treatments to personalized multi-gene therapy predictions, said Dr. Manmeet Ahluwalia, M.D., M.B.A., Chief of Medical Oncology, Chief Scientific Officer and Deputy Director at Miami Cancer Institute, part of Baptist Health South Florida; and Co-Principal Investigator for the myCare-024-04 clinical study. Using Cellworks Singula TRI, we can simulate the molecular effects of cell signaling, drugs and radiation on patient-specific in silico diseased cells prior to treatment and then identify the magnitude of disease control and survival for specific anti-tumor strategies. The findings from using this approach in the myCare-024-04 study suggest that biosimulating guideline GBM therapies for newly diagnosed GBM patients can positively effect clinical outcomes.

The Cellworks Biosimulation Platform simulates how a patient's personalized genomic disease model will respond to therapies prior to treatment and identifies novel drug combinations for treatment-refractory patients. The platform is powered by the groundbreaking Cellworks Computational Omics Biology Model (CBM), a network of 7,000+ human genes, 30,000+ molecular species and 100+ signaling pathways. As part of the biosimulation process, personalized disease models are created for each patient using their cytogenetic and molecular data as input to the Cellworks CBM. The Cellworks platform analyzes the impact of specific therapies on the patients personalized disease model and generates a Singula biosimulation report with Therapy Response Index (TRI) scores from 0 to 100 that predict the efficacy of specific chemotherapies.

myCare-024-04 Clinical Study

Background

In this study, the Cellworks Singula Therapy Response Index (TRI) was used to prospectively predict the Overall Survival (OS) and Progression-Free Survival (PFS) in a retrospective cohort of 270 IDH wildtype GBM patients from the Cancer Genome Atlas (TCGA) with known clinical outcomes treated with physician prescribed therapies. The cohort included 162 males and 108 females with a median age of 57.5 years.

Methods

A mechanistic mulit-omcis biology model created for each patient using comprehensive genomic inputs allows biosimulation of downstream molecular effects of cell signaling, drugs and radiation on a patients personalized in silico disease model. Stratified random sampling was used to split the data into independent training (N=153) and validation (N=117) subjects. Multivariate Cox Proportional Hazard and Proportional Odds models were used to model OS and PFS as a function of the pre-defined Singula TRI and clinical thresholds. Cox Proportional Hazards (PH) regression and likelihood ratio (LR) tests were used on the independent validation subjects to assess the hypothesis that Singula is predictive of OS and PFS above and beyond standard clinical factors.

Results

Using Cellworks Personalized Therapy Biosimulation, Singula TRI was significantly predictive of OS and PFS in univariate analyses and remained significantly predictive in multivariate analyses, which included patient age, patient sex, MGMT methylation status and drug class.

Conclusions

Cellworks Singula TRI facilitates selection of optimal personalized therapies by providing patient-specific estimates of OS and PFS for 18 NCCN guideline GBM therapies. This information may be used to estimate increases in OS and PFS when comparing Singula TRI recommended therapies verses standard care. These positive results suggest the utility of biosimulation-informed therapy selection to improve survival of GEA patients.

About Cellworks Group

Cellworks Group, Inc. is a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology. Using innovative multi-omics modeling, computational biosimulation and Artificial Intelligence heuristics, Cellworks predicts the most efficacious therapies for patients. The Cellworks unique biosimulation platform is a unified representation of biological knowledge curated from heterogeneous datasets and applied to finding cures. Backed by UnitedHealth Group, Sequoia Capital, Agilent and Artiman, Cellworks has the worlds strongest trans-disciplinary team of molecular biologists, cellular pathway modelers and software technologists working toward a common goal attacking serious diseases to improve the lives of patients. The company is based in South San Francisco, California and has a research and development facility in Bangalore, India. For more information, visit http://www.cellworks.life and follow us on Twitter @cellworkslife.

All trademarks and registered trademarks in this document are the properties of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220606005437/en/

Barbara ReichertReichert Communications, LLC[emailprotected]415-225-2991

Michele Macpherson, Chief Business OfficerCellworks Group, Inc.[emailprotected]650-346-9980

Source: Cellworks Group, Inc.

Original post:
Cellworks Singula TRI Provides Personalized OS and PFS Predictions for 18 NCCN Guideline GBM Therapies - StreetInsider.com

The forums at analytica invite visitors to practical presentations and panel discussions.

Live in Munich again at last: When analytica, the worlds leading trade fair for laboratory technology, analysis and biotechnology, opens its doors from June 21 to 24, around 900 exhibitors will present their innovations. The industry is particularly looking forward to in-person dialog. There are ample opportunities for this at the trade fair stands, as well as at the analytica conference, in the forums and during the many other accompanying events. Nothing beats a real get-together, says Armin Wittmann, Exhibition Director for analytica. The attractive analytica supporting program brings the laboratory of tomorrow to life and facilitates the exchange of know-how, experience and ideas.

The analytica conference, the scientific high point of analytica, will take place on the first three days of the trade fair in the ICM, right next to the exhibition halls. Whether its nanoplastics, cancer diagnosis or antibiotic-resistant germs in the water cycle: In nearly 200 presentations and a poster show, renowned scientists from all over the world will discuss what modern analytics is capable of today, where its limits currently lie and how these can be overcome in future. The multifaceted program was put together by the German Chemical Society (Gesellschaft Deutscher Chemiker, GDCh), the German Biochemistry and Molecular Biology Society (Gesellschaft fr Biochemie und Molekularbiologie, GBM) and the German Society for Clinical Chemistry and Laboratory Medicine e.V. (Deutsche Vereinte Gesellschaft fr Klinische Chemie und Laboratoriumsmedizin, DGKL).

The megatrend of digitalization will be a common thread through the analytica conference program, as well as through the exhibition halls. In the Digital Transformation special show in Hall B2, visitors can experience automated workflows, networked devices and robots in action. In the neighboring forum of the same name, Agilent, Merck, Mettler Toledo, Thermo Fisher Scientific and many other companies will explain their concepts for Laboratory 4.0 in 30-minute presentations. The industry association SPECTARIS will provide an overview of the current status of a uniform OPC-UA interface for German manufacturers.

The Biotech forum (Hall A3), the Occupational Health and Safety forum and the analytica forum (both in Hall B1) likewise invite visitors to practical presentations and podium discussions. Among the highlights in the analytica forum are the expert rounds on COVID-19 research on June 22 and 23, with the likes of Professor Jonas Schmidt-Chanasit from the Bernhard Nocht Institute for Tropical Medicine in Hamburg and Professor Helga Rbsamen-Schaeff, Leopoldina member and founder and Supervisory Board member of the biopharmaceutical company AiCuris. The exact dates will be announced shortly on the analytica website.

The German biotech industry has emerged as a solution to problems during the pandemic and has collected more capital in the past two years than ever before. The Finance Days on June 23 and 24 at the Biotech forum in Hall A3 will cover financing trends in the life sciences sector and answer questions about initial public offerings and global markets. With the personalized medicine themed day on June 24, analytica is also putting a particular focus on this promising sector. Representatives from associations, clusters and companies in the health care sector will discuss the potential of individualized therapies from various perspectives.

Safety in the laboratory is the number one priority in day-to-day work. The Occupational Health and Safety forum in Hall B2 will be devoted to this topic. This year at analytica, the company asecos will once again demonstrate accidents that can happen if hazardous substances are stored incorrectly in the laboratory live in their daily experimental presentations. There will also be presentations on lithium-ion batteries that are increasingly finding their way into laboratories and whose potential dangers should they be mishandled are often underestimated. The program is rounded out by presentations from companies such as Erlab, Bernd Kraft and a1-environsciences.

Anyone who wants to use analytica as a career booster can combine a trade fair visit with further training. The training and consulting firm Dr. Klinkner & Partner will be offering all-day seminars at analytica on selected topics, from laboratory IT to the validation of analytical methods. And last but not least analytica, together with the scientific society GDCh and the VBio, will be supporting young talent in the industry. As usual, the popular student information day will take place on the last day of the trade fair on June 24. Here, high-school graduates can learn about fields of study and occupational areas in chemistry, biotechnology and food chemistry.

Read more from the original source:
Inspiration for the laboratory of tomorrow - Chemie.de